Merck (MRK) Over-Hyped in Hep C, Says Wells Fargo (GILD) (ABBV)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
- Oppenheimer sees AI software winners as focus shifts to ROI
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
Gilead Sciences (GILD) PT Bumped Up at Nomura
April 10, 2014 7:37 AM EDTNomura Securities analyst Ian Somaiya reiterated a Buy rating and bumped his price target on Gilead Sciences (NASDAQ: GILD) from $120 to $121, saying not all HCV drugs created equal.
Somaiya said, "We are raising our revenue estimates for Gileads HCV franchise as we... More
Maxim Remains Positive on Gilead (GILD); Sovaldi is Compelling HCV Treatment from Cost-Benefit Perspective
April 9, 2014 8:50 AM EDTGilead Sciences (Nasdq: GILD) is up early Wednesday following positive commentary out of Maxim Group. The firm has Gilead at Buy with a price target of $101.
Analyst Jason Kolbert, commented, Gilead was pilloried again yesterday for developing a drug (Sovaldi) with the highest efficacy and fewest side effects, but at a high (but not the highest) price for a new... More
Major PBM Looks to Stem Gilead Sciences' (GILD) Hepatitis C Profits
April 8, 2014 6:56 AM EDTGilead Sciences (Nasdaq: GILD) is on watch Tuesday as one major pharmacy benefits manager (PBM) is looking to stem some of its costs.
Bloomberg reported that Express Scripts (Nasdaq: ESRX) could move to... More
